Drug profile · INN
inclisiran
LEQVIO
inclisiran (LEQVIO) is a pcsk9 mrna rnai inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Cardiovascular system (C10) C10AX
Patents linked 0
Pipeline programs 10
News articles 0
Drug details — inclisiran
- Class
- Cardiovascular system (C10)
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.83
Quick answer
inclisiran (LEQVIO) is a pcsk9 mrna rnai inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN inclisiran
Brand LEQVIO
Mechanism PCSK9 mRNA RNAi inhibitor
Target PCSK9 mRNA
Therapeutic class Cardiovascular system (C10)
ATC code C10AX
Originator Novartis Pharmaceuticals
Mechanism of action
PCSK9 mRNA RNAi inhibitor
Primary target: PCSK9 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is inclisiran?
inclisiran (LEQVIO) is a pcsk9 mrna rnai inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for inclisiran?
LEQVIO is a marketed brand name for inclisiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.